Skip to main content
Log in

Psychiatric Disorders with Anti-TNFalpha Treatment: An Adverse Drug Reaction to Keep in Mind

  • Abstract
  • Published:
Drug Safety Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Kaufman KR. Etanercept, anticytokines and mania. Int Clin Psychopharmacol 2005; 20: 239–41

    Article  PubMed  Google Scholar 

  2. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000; 342: 763–9

    Article  PubMed  CAS  Google Scholar 

  3. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during antitumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862–9

    Article  PubMed  CAS  Google Scholar 

  4. Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003; 48: 1093–101

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Théophile, H., Debray, B., Miremont-Salamé, G. et al. Psychiatric Disorders with Anti-TNFalpha Treatment: An Adverse Drug Reaction to Keep in Mind. Drug-Safety 31, 885 (2008). https://doi.org/10.2165/00002018-200831100-00073

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200831100-00073

Keywords

Navigation